Stock Market Profiles

EXEL (EXELISIS INC) P/E: 800 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $.31 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.24 DIVIDEND: none Exilixis is a pharmaceutical company specializing in cancer drugs. The company is up already over 60% YTD. It is heavily owned by the major institutions. In each of the last 4 quarters, EXEL has beat Wall Street expectations, according to Estimize. The last two quarters have been profitable, and the company has set its expectations for profitable quarters in the future. Previously, the company posted consistent losses. Revenue increased approximately 550% on a year-over-year basis, while collaborative revenue doubled. EXEL has partnerships with Roche and GlaxoSmithKline. Cabometyx, a rectal cancer drug, is its largest revenue source in the latest quarter and most recent drug launch for the company. Exelixis announced that their R&D budget decreased due to decreased costs in one of their drug s...

AMGN P/E: 16.1 GAAP EPS Y-O-Y GROWTH LAST QUARTER: $.22 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.62 DIVIDEND: 2.54% Amgen is a leading biotech company with a solid financial foundation. It has managed to reduce its spending on research and development while increasing revenue through its sales of established drugs such as Enbrel, and Prolia. The company has several rapidly growing drugs that are newer to the market, with many drugs in the company's pipeline. In its last quarter, Amgen posted 7.7% revenue growth with 7.5% net income growth. The company spent less, however, in the most recent quarter when compared with the comparable quarter from the prior year, on research and development. The reduction in operating margin came from an increased interest expense in the quarter. Although the company spent less on research and development, its revenue did increase. Amgen is continuing to innovate despite reduced research and development b...